Triad

Insomnia, Neurotic depression, Depression + 8 more

Treatment

20 Active Studies for Triad

What is Triad

Doxepin

The Generic name of this drug

Treatment Summary

Calcium carbonate is a medication used to reduce stomach acid. It works by neutralizing the hydrochloric acid in the stomach, which can help to reduce symptoms associated with heartburn, upset stomach, and acid indigestion. Calcium carbonate may also be taken as a nutritional supplement or to treat calcium deficiency.

Sinequan

is the brand name

image of different drug pills on a surface

Triad Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Sinequan

Doxepin

1969

307

Effectiveness

How Triad Affects Patients

Gastric-peptic disease is caused by an imbalance between protective substances like mucus, bicarbonate, and prostaglandin and aggressive substances like hydrochloric acid, pepsin, and bacteria called H. pylori. Antacids help to restore the balance of these substances, reducing pepsin activity and increasing bicarbonate and prostaglandin secretion. Calcium carbonate has an acid-neutralizing capacity of 58 mEq/15 ml. When taken as a supplement, it helps to increase calcium stores in the body.

How Triad works in the body

Calcium carbonate is a salt that helps to reduce the acidity of stomach secretions by neutralizing hydrochloric acid. It also blocks the action of pepsin, an enzyme involved in digestion. This helps protect the stomach lining and can increase the production of bicarbonate and prostaglandins. When calcium carbonate neutralizes hydrochloric acid, it forms calcium chloride, carbon dioxide, and water. About 90% of calcium chloride is converted to calcium carbonate and calcium phosphate, which are not easily dissolved.

When to interrupt dosage

The proposed dosage of Triad is contingent upon the diagnosed condition, for example Gastric Ulcer, Dyspepsia and Acid dyspepsia. The amount of dosage also relies upon the method of delivery (e.g. Tablet or Oral) featured in the table beneath.

Condition

Dosage

Administration

Insomnia

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurotic depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depression

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Generalized Anxiety Disorder

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neuropathic Pain

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Itching

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Behcet Syndrome

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Alcoholism

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Depressive Disorder, Major

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Neurodermatitis

, 10.0 mg/mL, 10.0 mg, 25.0 mg, 50.0 mg, 75.0 mg, 100.0 mg, 0.05 mg/mg, 150.0 mg, 3.0 mg, 6.0 mg, 5.0 %

Oral, , Solution, concentrate, Solution, concentrate - Oral, Capsule, Capsule - Oral, Topical, Cream - Topical, Cream, Tablet, Tablet - Oral, Solution, Solution - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Triad Contraindications

Condition

Risk Level

Notes

untreated narrow angle glaucoma

Do Not Combine

Pulse Frequency

Do Not Combine

Urinary Retention

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Doxepin may interact with Pulse Frequency

There are 20 known major drug interactions with Triad.

Common Triad Drug Interactions

Drug Name

Risk Level

Description

4-Methoxyamphetamine

Major

Doxepin may increase the vasopressor activities of 4-Methoxyamphetamine.

Acepromazine

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Acepromazine.

Aclidinium

Major

The risk or severity of adverse effects can be increased when Doxepin is combined with Aclidinium.

Alfuzosin

Major

Doxepin may increase the hypotensive activities of Alfuzosin.

Aripiprazole

Major

Doxepin may increase the orthostatic hypotensive, hypotensive, and antihypertensive activities of Aripiprazole.

image of a doctor in a lab doing drug, clinical research

Triad Novel Uses: Which Conditions Have a Clinical Trial Featuring Triad?

75 active clinical trials are presently analyzing the potential of Triad in treating Hypovitaminosis D, Fracture and Calcium and Vitamin D Deficiency Disorders.

Condition

Clinical Trials

Trial Phases

Generalized Anxiety Disorder

198 Actively Recruiting

Not Applicable, Early Phase 1, Phase 2, Phase 4, Phase 1, Phase 3

Depressive Disorder, Major

0 Actively Recruiting

Insomnia

0 Actively Recruiting

Depression

299 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Alcoholism

5 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Neurotic depression

0 Actively Recruiting

Depressive Disorder, Major

20 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Early Phase 1

Itching

4 Actively Recruiting

Phase 3, Not Applicable, Early Phase 1

Behcet Syndrome

1 Actively Recruiting

Not Applicable

Neuropathic Pain

4 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Neurodermatitis

0 Actively Recruiting

Triad Reviews: What are patients saying about Triad?

4

Patient Review

5/18/2010

Triad for Migraine Headache

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about triad

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does triad mean three?

"A trio is three people or things considered as one unit."

Answered by AI

Do the triads still exist?

"Although they are not as prevalent as they used to be, there are still remnants of former gangs and societies. The governments of Malaysia and Singapore have taken measures to reduce crime, which has caused these societies to go into hiding (especially in Singapore). Triads were also common in Vietnamese cities with large Chinese populations (especially Cantonese and Teochew)."

Answered by AI

What are examples of triads?

"A triad is a three-member social group. Triads are said to be more stable than dyads and they allow for more complex relationships. An example of a triad would be three college students that share an apartment. So next time you hear someone say that 'three's a crowd,' you can respond by saying that three is actually a triad."

Answered by AI

Clinical Trials for Triad

Image of Weill Cornell Medicine, Starr Facility in New York, United States.

Transcendental Meditation for Burnout

18+
All Sexes
New York, NY

The goal of this study is to learn if a meditation intervention called Transcendental Meditation or TM can be used in a small department at Weill Cornell Medicine to help reduce employees' levels of burnout, anxiety, insomnia, and depression as well as to determine the feasibility and acceptability of the meditation practice by Weill Cornell employees. The main question the study aims to answer is whether: • Levels of burnout, anxiety, insomnia, and depression will be decreased, and overall mental well-being will improve over a 3.5-month period before and after TM intervention. Participants will attend 9 sessions total (8 group sessions and 1 individual session) with a certified TM instructor from The David Lynch Foundation Institute for Mental Health and Resilience where they will gain experience in proper TM techniques. Also, participants will conduct 2 of their own TM sessions at home daily during the course of this study.

Waitlist Available
Has No Placebo

Weill Cornell Medicine, Starr Facility

Joseph Osborne, MD, PhD

Image of McLean Hospital in Belmont, United States.

D-Cycloserine + TMS for Mental Health

18+
All Sexes
Belmont, MA

This study is testing whether combining a rapid form of transcranial magnetic stimulation (TMS), an oral medication called d-cycloserine (DCS), and therapy can improve brain flexibility and emotional control in adults experiencing moderate-to-severe depression, anxiety, or trauma symptoms. TMS is a non-invasive treatment that uses gentle magnetic pulses to stimulate specific areas of the brain. In this phase of the study, all participants receive active accelerated TMS (delivering multiple brief sessions in a single day) along with DCS, a medication that helps enhance brain learning and plasticity. Participants will be randomly assigned to have TMS directed at one of two brain targets: a region called the precuneus (identified using personalized brain scans) or the dorsolateral prefrontal cortex (a standard area for mood treatment). Afterward, participants are randomly assigned to complete three weeks of either therapist-led talk therapy (a modified Unified Protocol) or self-guided educational videos and readings. The main goals are to determine which brain stimulation target works best and to see whether therapist-led therapy leads to more lasting symptom relief and brain changes compared to self-guided education.

Phase 2
Waitlist Available

McLean Hospital

Image of Wahwala Iyohlogya/Peaceful Means in Pine Ridge, United States.

Lakota Family Acceptance Program for Relationship or Family Issues

Any Age
All Sexes
Pine Ridge, SD

Although research documents the concerning rates of mental and behavioral health problems (e.g., substance use/initiation) among Indigenous LGBTQ2S+ youth, there is very little known about how to prevent these deleterious issues that devastate Indigenous communities. The study will include \~40 families (Lakota LGBTQ2S+ youth and caregivers) in Rapid City, SD (20 families (10 FAP; 10 wait-list control) and on the nearby Pine Ridge Indian Reservation (10 FAP; 10 wait-list control). Following the baseline survey, families will be randomly assigned to the treatment or wait-list control. Participants will complete an immediate post-test and 6-month follow-up survey to test the hypotheses that FAP will lead to changes in targets, specifically increases in caregiver accepting behaviors, youth and caregiver connection to Lakota culture, family bonding, and youth future orientation and decreases in caregiver rejecting behaviors, caregiver harsh parenting, and youth internalized homo/bi/transphobia compared to the control condition. The researchers will also examine the hypotheses that there will be reductions in deleterious primary outcomes (depressive symptoms, anxiety symptoms, suicidality) and secondary outcomes (alcohol and drug use/initiation and dating and sexual violence victimization and perpetration) among youth in the treatment conditions compared to the control condition. Additionally, the researchers will assess the acceptability and feasibility of the FAP via program observations, post-session surveys, and exit interviews.

Waitlist Available
Has No Placebo

Wahwala Iyohlogya/Peaceful Means (+1 Sites)

Katie Edwards, PhD

Image of Northwestern Memorial Hospital in Chicago, United States.

Psychological Prehabilitation for Gastrointestinal Disease

18+
All Sexes
Chicago, IL

The goal of this clinical trial is to learn if a psychological program before surgery can help adults who have lasting stress from past medical experiences. The program is called PREPARE-GI. It is for adults having planned, complex surgery on the digestive system, also called gastrointestinal (GI) surgery. Many people who need complex GI surgery have been through a lot. They may have had many surgeries, hospital stays, or emergency visits. These experiences can leave lasting stress, worry, and low mood. These feelings can make recovery from surgery harder. The main questions this study aims to answer are: * Can researchers sign up enough participants, and will participants attend the program sessions and finish the surveys? * Does the program lower stress, worry (anxiety), and low mood (depression)? * Does the program lower pain and improve quality of life after surgery? * Does the program shorten hospital stays or lower return visits to the hospital or emergency room? Researchers will compare two groups. One group will take part in the PREPARE-GI program. The other group will get usual surgical care. Participants will be placed in a group by chance, like flipping a coin. Adults may be able to join if they: Are 18 or older Have complex GI surgery planned at Northwestern Memorial Hospital at least 8 weeks away Score high on a short survey about stress from past experiences Can complete the study in English All participants will: Answer survey questions about stress, worry, mood, body symptoms, pain, and quality of life. They will do this before surgery, then 1 month and 3 months after surgery. The surveys will take about 20 to 30 minutes to complete. Rate their pain on a scale from 0 to 10 after surgery. Allow researchers to review their medical records for information about their surgery and recovery. Participants in the program group will also meet one-on-one with a licensed psychologist for 8 sessions. Each session lasts about 1 hour and will take place either in person or by secure video from home. In the sessions, participants will learn skills to manage stress, handle difficult feelings, and prepare for surgery and recovery. Participants will be in the study for about 5 months. Participants in the program group will spend about 9 to 10 hours on the study. Participants in the usual care group will spend about 1 to 1.5 hours. This is a small study with 20 participants. The results will help researchers plan a larger study in the future.

Recruiting
Has No Placebo

Northwestern Memorial Hospital

Michael Rosen, MD

Have you considered Triad clinical trials?

We made a collection of clinical trials featuring Triad, we think they might fit your search criteria.
Go to Trials
Image of Summit Hyperbarics and Wellness in Boise, United States.

Hyperbaric Oxygen Therapy for Traumatic Brain Injury

18 - 75
All Sexes
Boise, ID

The goal of this study is to examine changes in cognitive functioning and post-concussive symptoms following hyperbaric oxygen therapy (HBOT) in current and former first responders with a history of traumatic brain injury. The main questions it aims to answer are: 1. Do cognitive functioning and post-concussive symptoms change after 40 HBOT sessions? 2. Do symptoms of PTSD, depression, and anxiety, or quality of life, change after treatment? Approximately 54 participants will: * Complete medical and behavioral health screening. * Complete cognitive tests and questionnaires before and after treatment. * Receive 40 HBOT sessions at 2.0 atmospheres absolute (ATA), twice daily with at least four hours between sessions. All participants will receive HBOT. There is no comparison group, so the study cannot determine whether HBOT caused any observed changes.

Phase 2
Recruiting

Summit Hyperbarics and Wellness

Steve Wyman, MD

Image of Attune Neurosciences, Inc. in San Francisco, United States.

Focused Ultrasound for Depression, Anxiety, and OCD

22 - 80
All Sexes
San Francisco, CA

This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201 device across seven candidate deep-brain targets in adults with subsyndromal-to-moderate depression, anxiety, or obsessive-compulsive disorder. Every session delivers active ATTN201 stimulation; there is no sham or placebo condition. Participants and the on-site study staff who deliver stimulation and administer the clinical scales are blinded to the brain target and to the stimulation parameters assigned for each session by a constrained Bayesian optimization algorithm.

Waitlist Available
Has No Placebo

Attune Neurosciences, Inc.

Attune Neurosciences Inc

Image of Columbia University Irving Medical Center - Milstein Hospital in New York, United States.

Music for Anxiety

18+
All Sexes
New York, NY

Many patients feel anxious before joint replacement surgery. This anxiety is common - affecting roughly 1 in 3 patients - and research has shown that patients who are more anxious before surgery tend to have more pain afterward and may need more pain medication during recovery. Listening to music before medical procedures has been shown to reduce anxiety in many types of surgery. In fact, a recent analysis of 20 studies found that music works about as well as anti-anxiety medication for calming patients before surgery, with about 1 in 4 patients experiencing a meaningful benefit. However, almost all of this research has been done in other types of surgery. No study has specifically tested whether letting patients listen to their own preferred music before hip or knee replacement surgery reduces their anxiety. This study will randomly assign 52 patients scheduled for hip or knee replacement surgery to one of two groups: one group will listen to music of their choice through noise-cancelling headphones while waiting for surgery (for at least 20 minutes), and the other group will receive the usual preoperative care without music. Patients will fill out a brief 6-question anxiety survey when they arrive in the preoperative area and again just before being taken to the operating room. The study will also ask patients about their pain, anxiety, and overall experience after surgery, and will review their medical charts to see how much sedation and pain medication was used during the procedure. If music is shown to reduce anxiety in this setting, it could be easily adopted by any hospital at very low cost, offering patients a simple, drug-free way to feel calmer before their surgery.

Recruiting
Has No Placebo

Columbia University Irving Medical Center - Milstein Hospital

Roshan P Shah, MD

Image of Steven A. Cohen Military Family Clinics at Red Rock, Colorado Springs in Colorado Springs, United States.

Parenting-STAIR Modular for PTSD and Depression

18+
All Sexes
Colorado Springs, CO

The goal of this clinical trial is to learn if a family-based treatment called Parenting-STAIR-Modular (PSTAIR-M) can help military parents recover from trauma, strengthen emotion regulation skills, and improve parent-child relationships. Participants will be trauma-exposed active-duty Service Members (SM) or their spouses who screen positive for PSTD and/or depression, and one identified child (ages 2-10). The main questions it aims to answer are: 1) Does PSTAIR-M reduce parental PTSD and depression symptoms, lower parenting stress, and improve child behavior compared to treatment-as-usual?; and 2) Is PSTAIR-M feasible and acceptable when delivered to military families stationed overseas? Researchers will compare PSTAIR-M to treatment-as-usual (TAU) to see if PSTAIR-M leads to greater improvements in parental PTSD, depression, parenting stress, emotion regulation, child maltreatment risk, and child behavior than usual care. Participants will: 1) attend 12-16 weekly, 1-hour online treatment sessions with their assigned clinicians, 2) complete three 1-hour online assessments administered by research staff, 3) engage with their child in three 15-30-minute online, observed play sessions, 4) have assessments and observed play sessions audio and video recorded.

Waitlist Available
Has No Placebo

Steven A. Cohen Military Family Clinics at Red Rock, Colorado Springs (+3 Sites)

Kathrine S Sullivan, PhD

Have you considered Triad clinical trials?

We made a collection of clinical trials featuring Triad, we think they might fit your search criteria.
Go to Trials
Image of Medical University of South Carolina in Charleston, United States.

CHW Support for Post-Traumatic Stress Disorder

18+
All Sexes
Charleston, SC

This pilot study will evaluate the feasibility, acceptability, and preliminary effectiveness of the Trauma Resilience and Recovery Program Plus (TRRP+), a Community Health Worker-enhanced intervention designed to improve behavioral health engagement and recovery among adult trauma survivors with unmet social needs. One hundred adult trauma patients admitted to the Medical University of South Carolina (MUSC) Level I Adult Trauma Center who screen positive for risk of posttraumatic stress disorder (PTSD) or depression and report at least one unmet social need will receive TRRP+ services. Participants will complete assessments at baseline, 1 month, and 3 months after enrollment. The study will also examine implementation barriers and facilitators to support future dissemination and scale-up of the intervention.

Waitlist Available
Has No Placebo

Medical University of South Carolina

Theresa Skojec, PhD

Image of Tactical Mind Research Coalition in Tampa, United States.

Non-Drug Treatments for Anxiety Disorder

18 - 70
All Sexes
Tampa, FL

RESYNC-BH is a research study evaluating a personalized, non-drug brain-and-body treatment approach for adults with ongoing behavioral health symptoms such as depression, anxiety, trauma-related symptoms, sleep problems, attention difficulties, or substance-use concerns. Rather than assigning treatment solely according to psychiatric diagnosis, treatment approaches are selected based on symptoms, physiologic measures, and clinical presentation. Treatment may include noninvasive neuromodulation, sensory stimulation, regulated breathing, and AIP-informed integrative psychotherapy. The study will evaluate whether personalized treatment approaches produce rapid and sustained improvements in behavioral health symptoms and functioning, and whether treatment response is accompanied by measurable changes in neurophysiologic, autonomic, cognitive, inflammatory, and behavioral measures. The study hypothesis is that meaningful clinical improvement is associated with measurable changes across brain, body, cognitive, and behavioral signals, and that early changes in these measures may help characterize treatment response and its durability. The long-term goal is to develop more objective and personalized methods for monitoring behavioral health treatment response.

Waitlist Available
Has No Placebo

Tactical Mind Research Coalition

Brian Pinkston, MD, MPH

Image of Stony Brook University in Stony Brook, United States.

Behavioral Activation for Depression and Autism

12 - 17
All Sexes
Stony Brook, NY

Autism spectrum disorder is characterized by differences in social communication/interaction and the presence of restricted/repetitive behaviors, with significant heterogeneity in terms of autistic features, language ability, and cognitive characteristics. About 2-3% of individuals in the United States are autistic, and most autistic individuals have co-occurring mental health conditions. Autistic people are 3-4 times more likely to experience depression than non-autistic people. Of the emerging depression treatment research with autistic people, none to date has focused on developing and testing a depression treatment for autistic youth with below average cognitive abilities - a group which comprises over 50% of the autistic community. Therefore, this study seeks to evaluate the feasibility (Aim 1), acceptability (Aim 2), and preliminary treatment effects (Aim 3) of an extension of Behavioral Activation for Depression in Autistic Adolescents (BA-A), adapted to meet the needs of cognitively lower functioning autistic youth.

Recruiting
Has No Placebo

Stony Brook University

Michelle Menezes, PhD

Have you considered Triad clinical trials?

We made a collection of clinical trials featuring Triad, we think they might fit your search criteria.
Go to Trials